Amplified TPM1 suppresses non-small cell lung cancer cells proliferation and metastasis

Fengling Xu1, Jiangfeng Lv2, Shuang Qin2

  • 1Blood Transfusion Department, Jinan City People's Hospital, People's Hospital Affiliated to Shandong First Medical University, Jinan, 271100, China.

Discover Oncology
|June 14, 2025
PubMed
Abstract

Insights

Tropomyosin 1 (TPM1) is downregulated in non-small cell lung cancer (NSCLC). Overexpressing TPM1 inhibits NSCLC cell proliferation and metastasis by regulating YAP1, offering a potential new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Tropomyosin 1 (TPM1) plays a role in tumor progression.
  • The specific role and mechanism of TPM1 in non-small cell lung cancer (NSCLC) require further investigation.

Purpose of the Study:

  • To elucidate the effect and mechanism of TPM1 in NSCLC.
  • To identify TPM1 as a potential therapeutic target for NSCLC.

Main Methods:

  • TPM1 expression analysis in NSCLC tissues and normal tissues using GEPIA.
  • Assessment of NSCLC cell proliferation, apoptosis, migration, and invasion following TPM1 overexpression.
  • Western blot analysis of TPM1, YAP1, and EMT-related proteins.
  • Co-immunoprecipitation (Co-IP) assay to confirm TPM1-YAP1 interaction.

Main Results:

  • TPM1 expression is decreased in NSCLC.
  • TPM1 overexpression inhibits NSCLC cell proliferation, migration, and invasion, while promoting apoptosis.
  • TPM1 overexpression upregulates E-Cadherin and downregulates Vimentin and N-Cadherin, indicating inhibition of epithelial-mesenchymal transition (EMT).
  • TPM1 binds to YAP1 and downregulates its expression; YAP1 overexpression partially reverses the inhibitory effects of TPM1.

Conclusions:

  • TPM1 is downregulated in NSCLC.
  • TPM1 overexpression inhibits NSCLC progression by regulating YAP1.
  • TPM1 presents a promising therapeutic target for NSCLC treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K